DYADIC INTERNATIONAL INC

A biotechnology platform company headquartered in Jupiter, Florida, Dyadic International develops and manufactures industrial enzymes and proteins using its proprietary C1 fungal expression platform. The company serves life sciences, food and nutrition, and bioindustrial markets with its Dapibus protein production platform, which enables rapid development and large-scale manufacturing of cost-effective enzymes, proteins, metabolites, and other biologic products. The platform is designed to reduce production timelines and costs compared to conventional manufacturing methods.

The company's pipeline includes DYAI-100, a C1-derived recombinant protein RBD vaccine candidate for SARS-CoV-2, which is in Phase 1 clinical development. Beyond its internal development efforts, Dyadic has established partnerships including a research and development agreement with VTT Technical Research Centre of Finland, joint development collaboration with a global food ingredient company, and sublicense agreements with multiple biotechnology firms including Abic Biological Laboratories and Alphazyme.

The company operates with a small employee base of six full-time staff. Dyadic was incorporated in Delaware and founded in 1979, with operations spanning the United States and international markets. The company is publicly listed on Nasdaq.